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The progressive organization of immune effectors into functional ectopic lymphoid struc-
tures, named tertiary lymphoid organs (TLO), has been observed in many conditions 
in which target antigens fail to be eliminated by the immune system. Not surprisingly, 
TLO have been recurrently identified in chronically rejected allografts. Although signif-
icant progress has been made over the last decades in understanding the molecular 
mechanisms involved in TLO development (a process named lymphoid neogenesis), the 
role of intragraft TLO (if any) in chronic rejection remains elusive. The prevailing dogma is 
that TLO contribute to graft rejection by generating and propagating local humoral and 
cellular alloimmune responses. However, TLO have been recently observed in long-term 
accepting allografts, suggesting that they might also be able to regulate alloimmune 
responses. In this review, we discuss our current understanding of how TLO are induced 
and propose a unified model in which TLO can play deleterious or regulatory roles and 
therefore actively modulate the kinetics of chronic rejection.
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iNTRODUCTiON: THe CHALLeNGe OF CHRONiC ReJeCTiON  
iN TRANSPLANTATiON
Vital organ failure is a life-threatening condition where a vital organ (i.e., kidney, heart, liver, or 
lung…) does not perform its expected function. Recent lifestyle changes in developed countries, and 
the increased incidence of chronic diseases such as hypertension, obesity, and diabetes, have set the 
stage for accelerated risk for, and the occurrence of, vital organ failure. As a result, vital organ failure 
is currently recognized as the leading cause of debility and premature death worldwide (www.who.
int). In France alone, the personal, societal, and economic consequences of vital organ failure have 
a cost of more than €70 billion a year (25% of total health expenditures).
Transplantation consists in the restoration of vital physiologic functions through the surgical 
substitution of a defective organ by a functioning graft retrieved from a donor. Patients with end-
stage vital organ failure depend on solid organ transplantation, which is their best (often their only) 
therapeutic option.
In clinical transplantation, the donor is from the same species but genetically different. 
Consequently, the immune system of the recipient inevitably recognizes the antigenic determinants 
(alloantigens) that differ between the recipient and the donor, particularly the highly polymorphic 
molecules from the major histocompatibility complex [i.e., human leukocyte antigen (HLA)] in 
humans. The alloimmune response that develops against the donor-specific HLA molecules is 
FiGURe 1 | Tertiary lymphoid organs in a chronically rejected renal 
transplant. Biopsy of a renal transplant was performed for progressive 
deterioration of graft function, suggestive of chronic rejection. (A) HES 
staining revealed nodular infiltrates of mononuclear cells within graft 
parenchyma (original magnification: left panel, ×20; right panel, ×200). 
(B) Immunostainings unraveled the organized distribution of T cells (CD3+, 
left panel) and B cells (CD20, right panel). Original magnification: ×200.
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responsible for tissue damage, which leads to the failure of the 
transplanted organ, a process named “rejection.”
In the absence of a clinically applicable protocol able to 
induce the specific tolerance of the allogenic transplant by the 
recipient’s immune system (1, 2), the prevention of rejection is 
currently dependent upon immunosuppressive drugs (3). These 
drugs produce generalized immunosuppression, which means 
that any reduction in immune responsiveness to the allograft is 
accompanied by reduced immunity to infections and malignant 
diseases. Chronic immune injuries that result from the incomplete 
blockade of the recipient’s alloimmune response (i.e., chronic 
rejection) are currently the main factor limiting graft function 
duration (4). No significant progress has been made on this issue 
over the last decades as highlighted by the stagnation of graft half-
life (5). A better understanding of the pathophysiology of chronic 
rejection is therefore a mandatory step in identifying innovative 
approaches that would prolong graft function duration.
iNTRAGRAFT TeRTiARY LYMPHOiD 
ORGANS (TLO)
Rejected grafts are characterized by interstitial infiltration of cel-
lular effectors, mainly T cells and macrophages, but also dendritic 
cells, NK cells, B cells, and plasma cells.
In contrast with acute rejection, where infiltrates exhibit no 
particular spatial organization, during chronic rejection immune 
cells tend to organize themselves in structures that morphologi-
cally resemble the secondary lymphoid organs.
Analyzing all sorts of human kidney grafts removed for termi-
nal chronic rejection, we and others showed that in the majority 
of chronically rejected grafts the immune cells were grouped, 
conferring a nodular organization to the infiltrate (6, 7). These 
nodules exhibited a highly organized microarchitecture with clear 
cell subset segregation: the core, made of the B cells intermingled 
with a network of follicular dendritic cells, was surrounded by 
T cells and mature dendritic cells. CD138-expressing plasma cells 
were found within or in close vicinity to TLO, suggesting that 
part of these cells differentiated locally. As in canonical secondary 
lymphoid organs the compartmentalization of the different cell 
subsets appeared to be mediated by gradients of homeostatic 
chemokines CCL21 (in the T cell area) and CXCL13 (in the B cell 
area). Furthermore, neolymphatic vessels and PNAd-expressing 
high endothelial venules (HEVs) were observed in the periphery 
of the nodules (8).
The structural organization of immune effectors observed in 
chronically rejected renal grafts (Figure 1) does not seem specific 
of this type of transplant since similar lymphoid structures have 
been observed in chronically rejected pancreas, livers, hearts (7, 
9–11), lungs (12), and even composite transplants (13–15). This 
phenomenon is not specific of the alloimmune setting either, 
since the very same lymphoid structures have previously been 
observed in various inflammatory conditions, including chronic 
infections, autoimmune diseases, and cancers (16, 17). Structural 
organization of immune effectors therefore appears as a generic 
response of the chronically stimulated immune system that can-
not eradicate targeted antigens.
Because the microarchitecture of organized immune infiltrates 
is highly reminiscent of that of secondary lymphoid organs, these 
lymphoid structures have been named TLO.
MOLeCULAR MeCHANiSMS iNvOLveD  
iN THe DeveLOPMeNT OF SeCONDARY 
LYMPHOiD ORGANS
Primary immune responses are initiated in secondary lymphoid 
organs, which are located at strategic sites where antigens are 
most likely to be encountered.
The development of secondary lymphoid organs, a process 
named lymphoid organogenesis, is initiated during embryo-
genesis independently of antigen recognition at predetermined 
sites as a result of complex interactions between hematopoietic, 
mesenchymal, and endothelial cells (18, 19). Lymphoid organo-
genesis can be schematically divided into two consecutive steps: 
first the induction, then the organization phase.
The induction phase depends on lymphoid-tissue inducer cells, 
which arise in the fetal liver. Under the influence of TRANCE 
(at sites of peripheral lymph node development) or IL-7 (at 
mucosal sites) lymphoid-tissue inducer cells express membrane-
bound lymphotoxin: a heterotrimer containing lymphotoxin α 
and lymphotoxin β that allow lymphoid-tissue inducer cells to 
interact with the lymphotoxin β receptor (LTβR) of stromal cells. 
Signaling through the LTβR initiates NFκB signaling in stromal 
cells, which promotes the production of homeostatic chemokines 
(18, 19).
Homeostatic chemokines are crucial for the organization 
phase. CXCL13 recruits circulating B cells to what becomes the B 
cell area of lymphoid tissues, and the T zone chemokines (CCL19 
and CCL21) attract T and dendritic cells to shape the T cell area 
FiGURe 2 | Graphical summary of our current understanding of intragraft lymphoid neogenesis. The main molecular mechanisms involved in the initiation 
(upper row) and the subsequent organization (middle row) of tertiary lymphoid organs (TLO) within transplanted organs are showed. The diverse functions of 
intragraft TLO and their respective impact on graft survival are presented (lower row).
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(18, 19). The lymphotoxin signaling pathway is also crucial in 
promoting the differentiation of HEVs, which are postcapil-
lary venules expressing specific adhesion molecules (known as 
addressins) that have a crucial role in lymphocyte trafficking to 
secondary lymphoid organs (18, 19).
MOLeCULAR MeCHANiSMS OF 
LYMPHOiD NeOGeNeSiS iN 
TRANSPLANTATiON
Chronic rejection provides optimal conditions for studying the 
molecular mechanisms involved in the development of TLO 
(Figure  2). Indeed, (i) TLO have systematically been detected 
in chronically rejected grafts; (ii) the antigens targeted by the 
immune system are known (recipient-mismatched HLA antigens 
of the transplanted tissues); and (iii) chronically rejected grafts 
are sometimes removed, providing a large amount of diseased 
tissue, which can be comprehensively analyzed.
In-depth analysis of a series of detransplanted human renal 
grafts revealed the heterogenous nature of the cellular composi-
tion of TLO (8). Two types of B cell nodules could be identified: 
nodules composed of a uniform CD20pos B cell population express-
ing IgD and Bcl-2 were similar to primary follicles, while nodules 
with a core of CD20posIgDnegBcl-2neg B cells, highly expressing 
Bcl-6 that had pushed aside the CD20posIgDposBcl-2pos B cells, 
resembled secondary follicles, i.e., germinal centers (8). The ratio 
between these two types of structures differed between samples, 
and the number of ectopic germinal centers did not increase with 
the quantity of primary nodules. The phenotypic heterogeneity of 
TLO correlated more with the expression profile of a set of genes 
(CCL19, CCL21, CXCL12, CXCL13, CCR7, CXCR4, and CXCR5) 
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involved in the formation and the maintenance of canonical 
secondary lymphoid organs (i.e., the lymphoid organogenesis 
described in the previous section) (18, 19). The complete reca-
pitulation of this genetic program in chronically rejected grafts 
resulted in the generation of fully functional ectopic germinal 
centers that allowed for the efficient maturation of B cells into 
memory B cells and plasma cells (Figure 2). In contrast, when 
this recapitulation was incomplete, local B cell maturation was 
impeded (8). These results highlighted the similarity between the 
molecular processes involved in the development of canonical 
secondary lymphoid organs and those involved in the organiza-
tion of immune effectors during chronic inflammation, a process 
named lymphoid neogenesis.
If the molecular mechanisms responsible for the organiza-
tion and maintenance of secondary lymphoid organs and TLO 
appear similar, the initiation of the cascade is likely to be different 
(Figure 2). The formation of secondary lymphoid organs in the 
embryo is developmentally programed and results from the inter-
action between lymphotoxin-α1β2-expressing lymphoid-tissue 
inducer cells and lymphotoxin-β receptor-expressing stromal 
organizer cells (18, 19). In contrast, TLO development seems 
independent of lymphoid-tissue inducer cells (20, 21). Yet, sev-
eral studies have documented the importance of the lymphotoxin 
pathway in lymphoid neogenesis (21, 22), including in a trans-
plantation setting (23), by demonstrating that the development of 
TLO was abolished by treatment with inhibitory LTβR–Ig fusion 
protein. We must then ask who provides lymphotoxin signaling 
in the chronic rejection setting. Beyond lymphoid-tissue inducer 
cells, lymphotoxin-α and lymphotoxin-β are also expressed 
by activated lymphocytes (24). It is therefore conceivable that 
activated T and/or B cells replace lymphoid-tissue inducer cells 
to initiate lymphoid neogenesis in rejected grafts (Figure  2) 
as already demonstrated for the induction of TLO in the gut 
(21). Another possibility is that lymphotoxin is dispensable for 
the formation of TLO. Lymphotoxin-α and lymphotoxin-β are 
two related members of the large TNF ligand family (25). Since 
homologous genes and gene products often have redundant 
physiological functions, it seems reasonable to propose that 
other ligands and/or receptors of the TNF superfamily could 
act as alternative pathways for TLO induction (Figure  2). In 
line with this hypothesis, the provision of the alternative LTβR 
ligand LIGHT (aka tumor necrosis factor superfamily member 
14) by activated T cells infiltrating inflamed pancreas have been 
shown to be crucial for the formation of TLO (26). Furthermore, 
TNF-α, which is produced within rejected grafts (27), has been 
shown to be critical for the development of TLO in a murine 
model of atherosclerosis (20). TNF-α does not bind to LTβR but 
to distinct TNF receptors (25). Using apolipoprotein E-deficient 
mice, which spontaneously develop atherosclerotic lesions in 
their aorta, the Antonino Nicoletti’s group recently demonstrated 
that the blockade of LTβR signaling had no effect, whereas that 
of TNFR1/2 signaling reduced the expression of homeostatic 
chemokines and the subsequent development of TLO (20). 
Finally, it has recently been reported that IL-17 produced by 
CD4+ T cells (i.e., Th17 cells) was essential for the formation 
of both (i) TLO in the central nervous system of mice during 
experimental autoimmune encephalomyelitis (the animal model 
of multiple sclerosis) (28) and (ii) the development of inducible 
bronchus-associated lymphoid tissue, an ectopic lymphoid tissue 
that forms in the lungs after pulmonary inflammation (29, 30). 
In the latter setting, IL-17 acted by triggering the expression of 
homeostatic chemokines independently of lymphotoxin signaling 
(Figure 2). If this hypothesis was proven true in transplantation, 
initiation of lymphoid neogenesis in chronically rejected grafts 
could therefore be totally independent of both lymphoid-tissue 
inducer cells and the lymphotoxin/TNF pathway. Interestingly, 
we have recently reported that a Th17 polarization of CD4+ 
T cells infiltrating the graft was associated with increased TLO 
development during clinical chronic rejection (31).
It is conceivable that instead of conflicting with each other, 
these different works reveal the fact that several pathways can 
promote the initiation of TLO depending on the initiating events. 
This hypothesis was recently substantiated by the demonstration 
that the development of bronchus-associated lymphoid tissue 
was triggered by different pathways according to the pathogen 
responsible for lung inflammation (29).
While significant progress has been made in the identification 
of the molecular mechanisms that participate to the development 
of TLO, the endogenous signals capable of inhibiting the lymphoid 
neogenesis are far more elusive. Through evaluation of synovial 
tissues from rheumatoid arthritis patients it has been recently 
reported that low interleukin-27 (IL-27) expression corresponds 
with an increased incidence of TLO and gene signatures associ-
ated with their development and activity. The presence of synovial 
TLO was also noted in mice deficient in the IL-27 receptor after 
the onset of inflammatory arthritis (32). IL-27 might therefore 
represent a negative regulator of TLO development. Whether this 
is also true for chronic rejection remains to be demonstrated.
DO iNTRAGRAFT TLO PROMOTe 
CHRONiC ReJeCTiON?
Tertiary lymphoid organs differ from canonical secondary 
lymphoid organs inasmuch as they develop in an inflammatory 
milieu (31, 33), enriched in neoantigens released from injured tis-
sue and trapped by defective lymphatic drainage (34). Comparing 
the cellular composition of TLO of chronically rejected grafts 
with one of the secondary lymphoid organs, we observed a drastic 
increase in the percentage of activated and memory CD4+ T cell 
in intragraft TLO and a symmetric decrease in T regulatory 
subsets (IL-10-producing Tr1 cells and Foxp3pos Tregs) in both a 
murine experimental model and human samples (33, 35).
These peculiarities suggest that the local immune response that 
develops in intragraft TLO might be less tightly regulated than in 
secondary lymphoid organs and are therefore more aggressive. In 
line with this hypothesis, we (33) and others (23) have shown that 
intragraft TLO are a major site where B cell tolerance breakdown 
occurs during chronic rejection (Figure 2). Interestingly, the gen-
eration of autoantibodies following solid organ transplantation 
has long been reported to correlate with chronic rejection, and 
the deleterious impact of some autoantibodies on graft survival 
has been demonstrated (36, 37). Furthermore, comparing the 
alloimmune responses elicited in intragraft TLO, spleen, and 
draining lymph nodes in a rat model of chronic rejection, our 
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group observed increased production of anti-HLA antibodies in 
TLO as compared with canonical secondary lymphoid organs 
(35). Not only were the humoral alloimmune responses elicited 
in TLO quantitatively enhanced but they also displayed a more 
diverse repertoire, a finding that we confirmed in the clinical 
setting by the analysis of chronically rejected human kidney 
allografts (8).
Tertiary lymphoid organs could also contribute to chronic 
destruction of the graft through antibody-independent functions 
of B cells. B cells are indeed unique antigen-presenting cells because 
(i) they have an antigen-specific receptor (B cell receptor), which 
when engaged by surface-tethered antigens leads to the formation 
of an immunological synapse that coordinates cell signaling events 
and promotes antigen uptake for presentation on MHC class II 
molecules (38), even when the antigen is membrane-tethered or 
is present in limiting quantities and (ii) B cells have the capacity 
to clonally expand, thereby becoming the numerically dominant 
antigen-presenting cells. Interestingly, it has been reported that 
the presence of B cell clusters within the graft during rejection was 
associated with reduced graft survival and resistance to steroid 
therapy, independently of C4d (a breakdown product generated 
during classical complement pathway activation) deposition or 
alloantibody detection (39). Some authors have proposed that 
this could be due to the local presentation of antigen to effector 
T cells by intragraft B cells (40). This hypothesis is supported by 
experimental data from the group of Fadi Lakkis, who showed 
that in a murine skin graft model, TLO perpetuate the rejection 
process by supporting naïve T cell activation within the graft (41). 
Strikingly, the same authors also demonstrated that TLO generate 
T cell memory immune responses (41).
In addition to presenting antigen, B cells can also enhance 
T cell-mediated immune responses through the secretion of 
cytokines and chemokines. Studies from the group of Frances 
Lund (42) have shown that B cells can be functionally subdivided 
based on their cytokine profile. B cells activated in the presence 
of TH1-type cytokines (referred to as Be-1 cells) secrete IFNγ and 
IL-12 but not IL-4, IL-13, or IL-2. By contrast, B cells activated 
in the presence of TH2-type cytokines (Be-2 cells) secrete IL-2, 
lymphotoxin, IL-4, and IL-13 but make minimal amounts of IFNγ 
and IL-12. Both Be-1 and Be-2 cells seem able to produce IL-10, 
TNFα, and IL-6. The importance of B cell cytokines in promot-
ing T cell responses has been illustrated in several models. For 
example, in vitro generated effector B cells that produced either 
TH1- or TH2-type cytokines were shown to promote the activa-
tion and differentiation of naïve T cells into effector TH1 and TH2 
cells, respectively (43). The importance of B cell cytokines in pro-
moting T cell responses has been confirmed in vivo. In a murine 
model of Toxoplasma gondii infection, TNF production by B cells 
was shown to be required for the generation of an optimal TH1 
cell protective response (44). In another set of experiments, the 
generation of a protective TH2 memory response to H. polygyrus 
was shown to depend on IL-2-producing B cells (45). The exact 
role of cytokine-producing B cells in enhancing intra-TLO T cell 
responses remains to be evaluated.
Since grafts in which TLO were harboring germinal center 
reactions had a shorter life expectancy (Figure  2), we have 
proposed that lymphoid neogenesis could play a detrimental role 
during chronic rejection (8). However, the validity of this conclu-
sion is limited by the fact that only explanted grafts have been 
analyzed, i.e., organs displaying extreme rejection damage that 
are sometimes (notably in the case of renal grafts) removed after 
immunosuppressive therapy withdrawal. The definitive demon-
stration that TLO are involved in the pathophysiology of chronic 
rejection would require selectively impairing the development of 
intragraft TLO while leaving the rest of the recipient’s immune 
system unaffected. Addressing this issue is not trivial because, 
as discussed above, TLO share many biological pathways with 
canonical lymphoid tissue, and hence an adequate experimental 
model is not currently available. Therefore, most of the attempts 
to validate the data obtained in murine experimental models and 
in human detransplanted grafts have relied on graft biopsies. The 
identification of TLO within the grafts before the development of 
the lesions indeed appears as a prerequisite for confirming the role 
of lymphoid neogenesis in chronic rejection. This implies a study 
of protocol biopsies, which has long been introduced as standard 
follow up in transplantation (46). Unfortunately, the numerous 
studies aiming at evaluating the correlation between the presence 
of TLO in protocol biopsies and the later development of chronic 
rejection have reached conflicting conclusions (Table 1).
The absence of an unequivocal deleterious role for B cell 
clusters has led to the conclusion that these structures could be 
like “fish in a sunken ship,” i.e., although fish are frequently seen 
in a sunken boat, they play no role in the process responsible for 
the shipwreck.
iNTRAGRAFT TLO: FRieNDS AND FOeS?
An alternative explanation could reconcile these apparently 
conflicting results. As discussed above, the proportion of B cells 
that infiltrate chronically rejected kidney grafts does not correlate 
with the functionality of intragraft TLO (8). The attraction of B 
cells within inflamed tissue appears therefore to be a generic 
phenomenon with no intrinsic deleterious consequences on 
the graft. However, when intragraft B cells meet the appropriate 
microenvironment, and upon the complete recapitulation of 
the lymphoid organogenesis program, B cell nodules organize 
themselves into functional ectopic germinal centers, which 
harbor the development of a local aggressive immune response. 
Because graft biopsies provide only a very limited amount of tis-
sue (which is already an important limitation for evaluation in a 
patchy process such as lymphoid neogenesis), they do not allow 
for functional analysis of the ectopic lymphoid organs and are 
therefore inappropriate for analyzing the role of B cell clusters in 
rejected grafts.
Another layer of complexity has recently been brought into 
the picture by experimental evidence that certain B cell subsets 
are endowed with an immune regulatory role (47). For instance, 
IL-10-producing B cells have been shown to efficiently prevent 
the induction of autoimmune disease in several mouse models 
(48–50). Tolerance in transplantation is defined as the mainte-
nance of graft function in the absence of therapeutic immunosup-
pression for at least 12 months. About 100 tolerant patients have 
been identified among renal transplant recipients over the last 
decade (51). These patients, defined as “operationally tolerant,” 
TABLe 1 | Summary of biopsy-based studies evaluating the role of graft-infiltrating B cells.
Reference Population Biopsy indication Histologic criteria Key findings
KiDNeY ReCiPieNTS
Sarwal  
et al. (39)
51 patients Biopsy with acute graft rejection CD20+ cell count >275/HPF B cell clusters associated with glucocorticoid 
resistance and graft loss
Hippen  
et al. (58)
27 patients Biopsy with Banff 1A or 1B acute rejection CD20+ if “strong and diffuse 
staining”
CD20+ correlated with steroid-resistance 
rejection and reduced graft survival
Kayler  
et al. (59)
120 patients Biopsy with first episode of acute cellular 
rejection
Cluster of ≥15 CD20+ cells in the 
tubulo-interstitial compartment
CD20+ clusters are not prognostic factors for 
glucocorticoid resistance and graft loss
Bagnasco  
et al. (60)
58 patients  
(74 biopsies)
Biopsy with type 1 and type 2 acute cellular 
rejection during the first year post-Tx
B cell-rich when ≥1 cluster 
containing 100 CD20+ cells/HPF
No correlation between B cell-rich biopsies and 
worst graft outcome
Scheepstra 
et al. (61)
50 patients  
(54 biopsies)
Biopsy with clinically suspect and 
histologically confirmed acute rejection
B cell (CD20+) count >275/HPF Presence of B cells does not correlate with 
response to conventional therapy or graft 
outcome
CD20+ cluster if >30 cells
CD20+ without the interposition 
of tubules
Hwang  
et al. (62)
54 patients  
(67 biopsies)
Biopsy with acute cellular rejection CD20+ count >275/HPF CD38+ B cells ± CD20+ B cells correlated with 
poor clinical outcomesCD38+ if >30% infiltration
Martin  
et al. (63)
18 patients Serial biopsies for 10 recipients with chronic 
dysfunction and 8 with long-term normal 
graft function
Plasma cells count Patients developing chronic rejection present 
plasma cells, DSA, and C4d depositions more 
often than control group on their biopsy
Cd4 deposits
DSA elution from biopsy
Abbas  
et al. (64)
50 patients Biopsy for cause Plasma cell-rich acute rejection if 
>10% plasma cells
Plasma cell-rich acute rejection correlated with 
a poor graft outcome when associated with 
DSA
HeART ReCiPieNTS
Yamani  
et al. (65)
140 patients Systematic biopsy Nodular endocardial infiltrates 
(quilty lesions)
Quilty lesions are associated with increased 
development of coronary vasculopathy at 1 year
Chu  
et al. (66)
285 patients Systematic biopsy Quilty lesions Patients with quilty lesions and no anti-HLA 
class II DSA are more likely to develop graft 
arteriosclerosis at 5 years
Hiemann  
et al. (67)
873 patients  
(9,713 biopsies)
Systematic biopsy Quilty lesions Quilty lesions are associated with an increased 
risk for stenotic microvasculopathy and a poor 
graft outcome
Zakliczynski 
et al. (68)
344 patients Systematic biopsy Quilty lesions Positive correlation between quilty lesions and 
an increased risk of acute rejection but not with 
the occurrence of coronary artery vasculopathy
Frank  
et al. (69)
79 patients  
(37 with DSA)
Biopsy with or without graft dysfunction Ratios of T:B cells and CD4:CD8 
T cells
Patients with DSA have lower CD4:CD8 T cell 
ratio than controls
T:B cell ratio was similar in patients with and 
without DSA
COMPOSiTe TiSSUe ReCiPieNTS
Hautz  
et al. (14)
6 human hand 
recipients  
(187 biopsies)
Systematic and for cause biopsies CD3, CD4, CD8, CD20 PNAd 
stainings
PNAd expression in graft vessels correlated with 
rejection and T- and B-cell infiltration
DSA, donor-specific antibodies; HLA, human leukocyte antigen; HPF, high power field; PNAd, peripheral lymph node addressin; Tx, transplantation.
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are healthy, do not exhibit more infections or malignancies than 
healthy volunteers, and do not display clinical evidence of immune 
incompetence (51). When compared with transplanted patients 
with stable graft function under pharmacologic immunosuppres-
sion, operationally tolerant patients exhibited an increase in both 
absolute number and frequency of total B cells (52). Furthermore, 
two independent microarray analyses of PBMC revealed a higher 
expression of B cell-related genes and their associated molecular 
pathways in tolerant recipients (53, 54). It is therefore conceivable 
that in certain conditions intragraft B cell infiltrate, instead of 
being neutral or deleterious, could actually promote graft survival 
(Figure  2). This theory has been nicely illustrated by murine 
experimental studies that recently reported the formation of 
TLO within tolerated allografts (55–57). If such a local protective 
response can prevent terminal failure of grafts, then not only 
would such samples having “tolerogenic” TLO be absent from 
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the studies based on the analysis of detransplanted grafts but it 
could also explain the difficulty of biopsy-based studies to reach 
an unequivocal conclusion.
CONCLUSiON
Transplanted organ expresses donor-specific alloantigens, which 
stimulate a recipient’s immune system. Prevention of acute rejec-
tion of the graft is achieved using a combination of non-specific 
immunosuppressive drugs that can only partially block the allo-
immune effectors. The residual enduring alloimmune response 
promotes immune injuries known as chronic rejection, the main 
cause of late allograft loss. As in other chronic immune diseases, 
immune effectors within chronically rejected allografts progres-
sively organize into functional TLO that display the same micro-
architecture as secondary lymphoid organs, a process known as 
lymphoid neogenesis. Because biopsy-based studies have reached 
conflicting conclusions regarding the pathological significance 
of these TLO, it has been proposed that the presence of TLO in 
rejected grafts is a non-specific response to local inflammation-
induced production of chemokines. While that can indeed some-
times be the case, it should not be excluded that under appropriate 
conditions, lymphoid neogenesis turns non-functional TLO into 
ectopic germinal centers, in which a local aggressive humoral 
immune response can be elicited. Alternatively, functional TLO 
can also regulate immune responses and slow down the destruc-
tion process.
Therefore, we propose that TLO be considered as active play-
ers, able to modulate the kinetics of the natural history of chronic 
rejection. Future works will determine if the versatility of TLO 
can be manipulated to design innovative therapeutic interven-
tions that would improve graft life expectancy.
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